Mercy Executive Named Among Top Data/AI Leaders in Nation
ST. LOUIS, Sept. 27, 2024 /PRNewswire/ -- Mercy's industry-leading work in data and artificial intelligence has placed Byron Yount, PhD, chief...
Day: September 27, 2024
Alpha Omega wins Best Digital Transformation Award at Unqork + AI Hackathon
VIENNA, Va., Sept. 27, 2024 /PRNewswire/ -- Alpha Omega, a leader in mission-focused technology solutions, proudly announces that we have been awarded...
Epic calls on Particle Health to approve release of resolution in patient privacy dispute
VERONA, Wis., Sept. 27, 2024 /PRNewswire/ -- Epic and our customers protect the privacy of many Americans' health data. At...
Hyivy Health Secures $2M Seed to Unlock New Model for Treating Pelvic Pain
Pelvic health startup Hyivy Health poised to offer better solutions to the 300M patients with pelvic floor dysfunction causing chronic...
Patients for Patient Safety US Applauds the Biden-Harris Administration for Prioritizing Patient Safety
WASHINGTON, DC / ACCESSWIRE / September 27, 2024 / On September 17th, World Patient Safety Day (WPSD), the Biden-Harris Administration...
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27,...
Introducing Compassion Center Austin: Pioneering Natural Wellness Solutions Through the Texas Compassionate Use Program (TCUP)
Compassion Center Austin introduces Texans to natural pain management and opioid risk reduction through the Texas Compassionate Use Program (TCUP)....
Humaneva Group Secures Major US Private Equity Investment to Accelerate Global Clinical Research Market Expansion
WARSAW, POLAND / ACCESSWIRE / September 27, 2024 / Humaneva Inc. has entered into a significant investment agreement with Viking...
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic painMIAMI, FL / ACCESSWIRE / September 27, 2024...
Burning Rock Announces Changes to Management and Board of Directors
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a...
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company...
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical...
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine)...
TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly...
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM,...
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and...
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA,...
33 Medical Wins 2024 Best Technology in Spine Award for Innovative NuvoDisc® Device
Boca Raton, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- 33 Medical, Inc., a leader in cutting-edge spinal health innovations, is...
WeightWatchers Announces Executive Leadership Transition
Independent Board Member Tara Comonte Will Serve as Interim Chief Executive OfficerSima Sistani Will Step Down as CEO and Director...
ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) --...